Physician profile
Debra Obrien
NPI 1780755447
$692.13
in general payments reported to CMS, 2019-2025
14 companies · $49.09 in 2025
The $49.09 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.44 · 2020: $94.94 · 2021: $86.10 · 2022: $156 · 2023: $124 · 2024: $83.38 · 2025: $49.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $103.61 | 2019-2023 | Vaxneuvance, Gardasil 9, M-M-R II |
| Sanofi Pasteur INC. | $99.39 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $83.41 | 2021-2022 | |
| Pfizer INC. | $82.50 | 2020-2025 | |
| Kaleo, INC. | $66.00 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $58.01 | 2019-2022 | |
| Corium, LLC | $44.14 | 2022 | |
| Glaxosmithkline, LLC. | $40.51 | 2019-2022 | |
| Cranial Technologies, INC | $30.01 | 2020-2023 | Doc Band |
| Alk-Abello, INC | $20.00 | 2025 | Neffy |
| Seqirus USA INC | $17.84 | 2024 | Flucelvax |
| Cumberland Pharmaceuticals, INC. | $16.74 | 2024 | Kristalose |
| Biomarin Pharmaceutical INC. | $15.52 | 2022 | |
| Lnhc, INC | $14.45 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.